Back to Authors

Zhao, Geoffrey

Mayo Clinic

Mayo Clinic

Citations 1

PD-1 prelimits both the cytotoxic and exhaustion potential in thymic CD8+ T cells and impacts the maintenance of peripheral tumor immunity
Mao, Zhiming , Hirdler, Jacob B. , Gicobi, Joanina K. , Maynes, Mark , Hsu, Michelle A. , Teske, Jacob J. , Li, Ying , Zhao, Geoffrey, Lucien-Matteoni, Fabrice, Silva, Henrique Borges da , Billadeau, Daniel D. , da Silva, Henrique Borges, Borges da Silva, Henrique , Teske, Jacob J , Maynes, Mark A , Dellacecca, Emilia R. , Zhang, Wenjing , Zhao, Geoffrey, Dong, Haidong

No container title available | January 18, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1101/2025.01.18.631253 Get It

Abstract Durable T cell immunity against cancer depends on the continual replenishment of effector CD8+ T cells. Thymic output has been correlated with favorable prognosis in cancer patients across a range of ages, suggesting that the thymus is an important source for replenishing T cells capable of controlling cancer progression. However, the effector potential of thymic mature CD8+ T cells and their regulation have not been clearly defined. In this study, we identified the ability of thymic single positive CD8+ T cells to gain effector potential after thymic selection, but they are subject to the regulation of PD-1. We found a previously undisclosed role of PD-1 in limiting both the cytotoxic and exhaustion potential of thymic and peripheral CD8+ T cells. Our results show that although PD-1 inhibition facilitates the expansion of effector CD8+ T cells, effector CD8+ cells gradually lose their antitumor activity within tumor tissues due to advanced exhaustion in the absence of PD-1. Thus, although the preset effector potential in thymic mature CD8+ T cells allows them to rapidly respond to malignant cells in the periphery, PD-1, as a checkpoint, is embedded in the thymic mature CD8+ T cells after positive selection to balance their effector function from exaggeration and exhaustion. Therefore, we propose that a strategy capable of upholding the cytotoxic capacity and avoiding exhaustion of CD8+ T cells during the early stages of PD-1 inhibition therapy is needed to achieve durable antitumor immunity.